M. Hauser

发表

Clinical Practices that can Combat Endemic Legal Opioid Dependence: Genetic Addiction Risk Score (GARS)Ã¢ÂÂ¢, KB220ZÃ¢ÂÂ¢, Comprehensive Analysis of Reported Drugs (CARD) and Electrotherapy

K. Blum, M. Febo, T. Simpatico, 2013 .

The Addictive Brain: All Roads Lead to Dopamine

Thomas J. H. Chen, K. Blum, D. Barh, 2012, Journal of psychoactive drugs.

GLOBAL OPIOID EPIDEMIC: DOOMED TO FAIL WITHOUT GENETICALLY BASED PRECISION ADDICTION MEDICINE (PAM™): LESSONS LEARNED FROM AMERICA.

K. Blum, D. Barh, R. Badgaiyan, 2017, Precision medicine.

Have We Hatched the Addiction Egg: Reward Deficiency Syndrome Solution System™

Margaret A. Madigan, K. Blum, D. Barh, 2013, Journal of genetic syndromes & gene therapy.

Understanding the Scientific Basis of Post-traumatic Stress Disorder (PTSD): Precision Behavioral Management Overrides Stigmatization

K. Blum, P. Thanos, M. Oscar-Berman, 2019, Molecular Neurobiology.

Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis.

K. Blum, R. Badgaiyan, D. Baron, 2018, Biomedical journal of scientific & technical research.

“Dopamine homeostasis” requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America’s drug epidemic

K. Blum, R. Badgaiyan, D. Baron, 2017, Journal of systems and integrative neuroscience.

Genetic Addiction Risk Score (GARS™) as a Predictor of Substance Use Disorder: Identifying Predisposition Not Diagnosis.

K. Blum, T. Simpatico, R. Badgaiyan, 2018, Current trends in medical diagnostic methods.

Genetic Addiction Risk Testing Coupled with Pro-Dopamine Homeostasis, and Electro Therapy, May Overcome Aberrant Reward Seeking Behaviors: Analytic Evidence

D., Ñ., K. Blum, 2018 .

Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD)

K. Blum, D. Baron, M. Hauser, 2019, Journal of systems and integrative neuroscience.

Would induction of dopamine homeostasis via coupling genetic addiction risk score (GARS®) and pro-dopamine regulation benefit benzodiazepine use disorder (BUD)?

K. Blum, D. Baron, M. Gold, 2018, Journal of systems and integrative neuroscience.

Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note.

William B. Downs, K. Blum, D. Barh, 2013, Journal of addiction research & therapy.

Americas’ opioid/psychostimulant epidemic would benefit from general population early identification of genetic addiction risk especially in children of alcoholics (COAs)

K. Blum, D. Baron, M. Hauser, 2019, Journal of Systems and Integrative Neuroscience.

In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing.

K. Blum, T. Simpatico, R. Badgaiyan, 2020, Current psychopharmacology.

The Benefits of Genetic Addiction Risk Score (GARS™) Testing in Substance Use Disorder (SUD).

K. Blum, D. Barh, P. Thanos, 2018, International journal of genomics and data mining.

Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.

William B. Downs, K. Blum, D. Barh, 2012, Journal of addiction research & therapy.

A Multi-Locus Approach to Treating Fibromyalgia by Boosting Dopaminergic Activity in the Meso-Limbic System of the Brain

Margaret A. Madigan, K. Blum, D. Barh, 2014, Journal of genetic syndromes & gene therapy.

Neurogenetics and nutrigenomics of reward deficiency syndrome (RDS): Stratification of addiction risk and mesolimbic nutrigenomic manipulation of hypodopaminergic function

Margaret A. Madigan, K. Blum, D. Barh, 2013 .

Kenneth Blum 1,5,6,8,10,11,12,15*, Marlene Oscar-Berman2, Elizabeth Stuller3, David Miller4,5, John Giordano6, Siobhan Morse6, Lee McCormick7, William Downs B5, Roger L Waite5, Debmalya Barh8, Dennis Neal9, Eric R Braverman1,10, Raquel Lohmann10, Joan Borsten11, Mary Hauser12, David Han13, Yijun Liu

K. Blum, D. Barh, M. Oscar-Berman, 2012 .

Buprenorphine Treatment for Opioid Use Disorder in Community‐Based Settings: Outcome Related to Intensity of Services and Urine Drug Test Results

M. Galanter, M. Hauser, J. Femino, 2020, The American journal on addictions.

Precision Behavioral Management (PBM): A Novel Genetically Guided Therapy to Combat Reward Deficiency Syndrome (RDS) Relevant to the Opiate Crisis

K. Blum, P. Thanos, T. Simpatico, 2020 .

Iatrogenic opioid dependence is endemic and legal: Genetic addiction risk score (GARS) with electrotherapy a paradigm shift in pain treatment programs

Margaret A. Madigan, K. Blum, M. Oscar-Berman, 2013 .

A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone

David E. Smith, K. Blum, M. Oscar-Berman, 2018, Substance use & misuse.

Neuropsychiatric Genetics of Happiness, Friendships, and Politics: Hypothesizing Homophily ("Birds of a Feather Flock Together") as a Function of Reward Gene Polymorphisms.

Margaret A. Madigan, K. Blum, M. Oscar-Berman, 2012, Journal of genetic syndromes & gene therapy.

Addiction by Any Other Name is Still Addiction: Embracing Molecular Neurogenetic/Epigenetic Basis of Reward Deficiency

William B. Downs, K. Blum, P. Thanos, 2020, Journal of addiction science.

Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility

K. Blum, R. Badgaiyan, M. Hauser, 2015, Addiction genetics.

Hypothesizing Benefits of the Incorporation of Genetic Addiction Risk Score (GARSRX™Rx™) and Dopamine Agonist Modalities (DAM) in Clinical Addiction Medicine.

K. Blum, M. Febo, T. Simpatico, 2014 .

NEUROGENETIC IMPAIRMENTS OF BRAIN REWARD CIRCUITRY LINKS TO REWARD DEFICIENCY SYNDROME (RDS) AS EVIDENCED BY GENETIC ADDICTION RISK SCORE (GARS): A CASE STUDY

Margaret A. Madigan, K. Blum, D. Barh, 2013 .

Translational Research to Uncover Diagnostic & Therapeutic Gene Targets Emerging in a Genomic Era: from Bench to Bedside

K. Blum, T. Simpatico, E. Braverman, 2012 .

Hypothesizing that designer drugs containing cathinones ("bath salts") have profound neuro-inflammatory effects and dangerous neurotoxic response following human consumption.

K. Blum, M. Febo, M. Gold, 2013, Medical hypotheses.

Increased DLPFC activity during moral decision-making in psychopathy

A. Raine, M. Hauser, R. Schug, 2009, Molecular Psychiatry.

Understanding the Importance of Dopaminergic Deficit in Reward Deficiency Syndrome (RDS): Redeeming Joy Overcoming "Darkness" in Recovery

K. Blum, M. Febo, R. Badgaiyan, 2015 .

Critical Analysis of White House Anti-Drug Plan

Margaret A. Madigan, K. Blum, R. Badgaiyan, 2017, Global journal of addiction & rehabilitation medicine.

Neuropsychiatric Genetics of Happiness, Friendships and Politics: A New Era in Understanding Social Interface

K. Blum, T. Simpatico, E. Braverman, 2012 .

The Cambridge Handbook of Substance and Behavioral Addictions

Derek D. Reed, Mariel S. Bello, Derek T. Y. Mann, 2020 .

Koenigs et al. reply

R. Adolphs, A. Damasio, D. Tranel, 2008, Nature.

The Benefits of Genetic Addiction Risk Score (GARS™) Testing in Substance Use Disorder (SUD).

K. Blum, D. Barh, P. Thanos, 2018, International journal of genomics and data mining.

Genetic Addiction Risk Score (GARS™) as a Predictor of Substance Use Disorder: Identifying Predisposition Not Diagnosis.

K. Blum, T. Simpatico, R. Badgaiyan, 2018, Current trends in medical diagnostic methods.